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Previous analysis of U.S. physician oﬃce visits (1993–2007) indicated that the medicalization of sleeplessness
was on the rise and had potentially negative implications for population health. Our study asks if the medicalization of sleeplessness at the level of patient-physician interaction has persisted over time. Using the most
recent years available (2008–2015) of the National Ambulatory Medical Care Survey we calculated nationally
representative estimates for four sleeplessness-related outcomes of physician oﬃce visits: sleeplessness complaint, insomnia diagnosis, and prescription of benzodiazepine and non-benzodiazepine sedative-hypnotics
(NBSH). To test for the signiﬁcance of the linear trajectory, we ran a series of bivariate linear models. We tested
three hypotheses grounded in the medicalization framework: if the medicalization of sleeplessness at the interactional level is continuing at a rate comparable to previous analyses, sleeplessness-related outcomes will
continue to increase signiﬁcantly over time (Hypothesis 1); NBSH prescriptions and insomnia diagnoses will
continue to outpace sleeplessness complaints (Hypothesis 2); and insomnia diagnoses and use of sedative-hypnotics will increase or remain concentrated among age groups who lack the changing sleep patterns and commonly occurring comorbidities associated with older age (Hypothesis 3). Support for these hypotheses was
mixed. Unlike previous analyses wherein all sleeplessness-related outcome trends were positive and statistically
signiﬁcant over time, regression analyses revealed a signiﬁcant negative NBSH prescription trend 2008–2015
(slope, b = −699,628, P < 0.05). No other associations were signiﬁcant. Younger age groups were most likely
to receive an insomnia diagnosis and NBSH prescription. These trends imply that the medicalization of sleeplessness at the level of patient-physician interaction may be on the decline. We suggest that increasingly negative
portrayals of sedative-hypnotics, conservative practice recommendations, and decreased direct-to-consumer
advertising for NBSH may decrease consumerism and physician compliance related to the medicalization of
sleeplessness. We conclude with a discussion on non-pharmaceutical methods of reducing sleeplessness relevant
to population health.

Background
Insuﬃcient sleep has become a well-recognized public health concern (Colten & Altevogt, 2006). Commonly occurring, transient sleeplessness is often the result of social factors including stress, grief, or
aging processes (Moloney, 2017). The tendency of medicalizing these
normal if uncomfortable life experiences via a medical diagnosis (i.e.,
insomnia) and treatment with prescription sedative-hypnotics is contentious because it is costly (Conrad, Mackie, & Mehrotra, 2010), fails
to address underlying behavioral or social issues (Moloney, 2017), and
may heighten population health risks via dangerous side eﬀects (e.g.,
cognitive impairment, falls, increased all-cause mortality) (American
Academy of Sleep Medicine, 2004; Kripke, Langer, & Kline, 2012).
∗

Given these risks, it is important to track trends over time in
sleeplessness complaints, insomnia diagnoses, and sedative-hypnotic
prescriptions, and examine the forces that shape their trajectories. The
present study builds on previous analyses of sleeplessness-related outcomes of U.S. physician oﬃce visits, 1993–2007 (Moloney, Konrad, &
Zimmer, 2011). We analyze the most recent available data (2008–2015)
and assess trends over a 23-year trend arc. We further contribute to the
literature by exploring shifts in public perception, practice recommendations, and direct-to-consumer advertising that may inﬂuence
the medicalization of sleeplessness at the level of patient-physician
interaction.
To contextualize our study, we ﬁrst oﬀer an overview of medicalization, its fueling factors, and related theoretical frameworks. We then
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Ambien). Physician compliance with patient request was also inﬂuenced by multiple constraints (e.g., time, limited non-pharmaceutical
resources) (Moloney, 2017).
While quantitative medicalization analyses are rare, a study using
the National Ambulatory Medical Care Survey (NAMCS), a nationally
representative survey of U.S. physician oﬃce visits, revealed that
sleeplessness complaints, insomnia diagnoses, and prescriptions for
older generation benzodiazepines (BDZ)1 and newer generation nonbenzodiazepine sedative-hypnotics (NBSH)2 increased signiﬁcantly
from 1993 to 2007 (Moloney et al., 2011). The trends were particularly
noteworthy among adults ages 18-646 as they lack the changing sleep
patterns and increased comorbidities associated with older age (Colten
& Altevogt, 2006). Beginning in 2006, insomnia diagnoses began to
outpace sleeplessness complaints. NBSH prescriptions grew 30-fold
over the study period, far outpacing all other trends. The authors
concluded that these trends were indicative of the medicalization of
sleeplessness at the level of patient-physician interaction (Moloney
et al., 2011). Subsequent analyses of NAMCS indicate that rates of insomnia diagnoses and sedative-hypnotic prescriptions continued to rise
between 2008 and 2012 (Ford et al., 2014; Kaufmann, Spira, Depp, &
Mojtabai, 2016).
As noted, the forces that inﬂuence the medicalization process evolve
over time and, since the previous analysis, news media and academic
literature have increasingly suggested that sedative-hypnotics are
harmful to health. A widely-publicized matched-cohort study from
2012 found that just 18–132 sedative-hypnotic doses increased the
hazard of death threefold (Kripke et al., 2012). Even when adjusting for
age, gender, smoking, body mass index, ethnicity, marital status, alcohol use, and prior cancer, patients prescribed > 132 doses in a year
had substantial elevations in incident cancer and mortality (Kripke
et al., 2012). Data from randomized controlled trials suggest multiple
mechanisms by which sedative-hypnotics may increase mortality including: acute lethality from higher doses (especially with polypharmacy), impaired motor and cognitive functions leading to accidents and/or falls, and chromosomal damage (Kripke et al., 2012).
Although the exact mechanism between sedative-hypnotic use and associated harms remains speculative, numerous organizations, including
the Food and Drug Administration, the National Institutes of Health, the
American College of Physicians, and the American Academy of Sleep
Medicine have issued stronger cautions and revised practice recommendations (National Institutes of Health, 2005; Qaseem,
Kansagara, Forciea, Cooke, & Denberg, 2016; Siebern & Manber, 2011).
It is uncertain, however, whether these changes in public perception
and practice recommendations have been accompanied by shifts in
diagnostic and treatment practices. To our knowledge, no current
analyses oﬀer a comprehensive look at recent sleeplessness-related
outcomes of physician oﬃce visits and compare these outcomes to
1993–2007 trends. To address this literature gap, we ask: Have oﬃcevisit outcomes related to the medicalization of sleeplessness persisted
over time?
Drawing on the most recent publicly available years of NAMCS
(2008–2015) we analyzed: 1) sleeplessness complaint, 2) insomnia diagnosis, and 3) BDZ and NBSH prescriptions. Provisional hypotheses
were that: (a) if the medicalization of sleeplessness is continuing at a
rate comparable to prior analyses, all study outcomes would continue to
increase signiﬁcantly over time (Hypothesis 1); NBSH prescriptions and

summarize previous work on the medicalization of sleeplessness before
describing our updated analyses. We present our results in contrast to
the previous analyses, and end with a discussion on non-pharmaceutical
methods of reducing sleeplessness relevant to population health.
1.1. Medicalization
Medicalization is the process by which formerly non-medical issues
come to be described, accepted, or treated as medical problems with
medical solutions (Conrad, 2007). Medicalization occurs at three, mutually-inﬂuential levels: 1) conceptual (medical deﬁnitions are created
and used); 2) institutional (disease conceptualizations are codiﬁed);
and 3) interactional (interaction between patient and healthcare practitioner) (Conrad, 2007). The conceptual level has long been considered
key to the medicalization process but recent scholarship has highlighted
the importance of interactional factors related to patient-practitioner
interactions (Clarke et al., 2011; Figert, 2011, pp. 291–307).
The medicalization literature is grounded in social constructionism
(Conrad, 1992). Thus, medicalization studies often document the
transformation of natural life processes or deviant behaviors into
treatable disorders (Davis, 2006). For instance, in the 1970's Conrad
documented the rise of hyperkinesis (now ADHD) as a means of controlling certain deviant behaviors in children (Conrad, 1992). Although
diagnosis construction may be conﬂicted and controversial, the processual outcomes are value-laden and impact the illness experience,
treatment, stigma (or lack thereof), and health expenditures (Barker,
2008; Brown, 1995; Conrad et al., 2010).
The factors that inﬂuence the medicalization process evolve over
time. Currently, the primary engines of medicalization are: consumerism (patients challenge medical authority, seek physician compliance), managed care (medical encounter cost-controls), biotechnology (genetics, pharmaceuticals, and direct-to-consumer
advertising), and physicians (gatekeepers to treatment) (Barbee,
Moloney, & Konrad, 2018; Conrad and Cockerham, 2013; Moloney,
2017). Further, as medicine's cultural and structural contexts continually evolve, scholars have proposed new medicalization-related
frameworks including biomedicalization (emphasizes the role of biomedicine and technology in illness and risk assessment) (Clarke et al.,
2011), healthicization (individuals are responsible for controlling their
health through personal strategies and/or commercially available products) (Hislop & Arber, 2003), and pharmaceuticalization (emphasizes
pharmaceutical drugs as solutions to medicalized conditions) (Williams,
Seale, Boden, Lowe, & Steinberg, 2008). Although the present work
uses the medicalization framework, we revisit these related constructs
in our Discussion.
1.2. Medicalization of sleep
According to Williams, the medicalization of sleep is “a complex,
contested, partial process in which some aspects of sleep are becoming
more medicalized than others” (Williams, Coveney, & Gabe, 2013).
Cultural (Hollan, 2013; Williams et al., 2013) and familial (Venn,
Arber, Meadows, & Hislop, 2008) factors inﬂuence both sleep patterns
and remedies for perceived dysfunction, as does the patient-physician
interaction (Moloney, 2017). Diagnoses of sleep apnea and the recently
recognized “shift-work sleep disorder” remain somewhat contested by
patients (Williams et al., 2013; Zarhin, 2015). Sleeplessness, lamented
throughout recorded history, appears to be increasingly medicalized at
the interactional level (Moloney, 2017).
A qualitative study of sleepless patients and their physicians found
that both parties typically recognized sleeplessness as the result of aging
processes or life stressors, yet diagnosed the problem as insomnia and
(reluctantly) treated it with sedative-hypnotics (Moloney, 2017). Physicians highlighted the role of direct-to-consumer advertising in inﬂuencing patients’ consumerist behavior (i.e., asking for heavily advertised, newer-generation non-benzodiazepine sedative hypnotics like

1
BDZ (e.g., Restoril), introduced in the 1960's to treat anxiety and insomnia,
were initially thought to have low risk of dependence and were widely prescribed. Two decades later, BDZ were recognized as addictive and deemed a
social problem. Nevertheless, they are still favored by older patients, who may
have used them for decades.
2
NBSH (e.g., Ambien), FDA-approved for insomnia in 1992, were promoted
through multi-million dollar advertisements as being safer than BDZ. However,
these claims have since been questioned and, as noted in this manuscript,
prescription recommendations have grown increasingly conservative.
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excluded from analyses. To compare Study 2 trends with Study 1
trends, national estimates for the outcomes of interest for Study 1 were
re-calculated to exclude CHC visits. These changes resulted in slightly
lower national estimates relative to those previously published (see
Fig. 1). (Moloney et al., 2011)

insomnia diagnoses would continue to outpace sleeplessness complaints
(Hypothesis 2); and insomnia diagnoses and use of sedative-hypnotics
would increase or remain concentrated among age groups who lack the
changing sleep patterns and comorbidities associated with older age
(Hypothesis 3).
Methods

Results

NAMCS data are collected annually by the National Center for
Health Statistics. Approximately 3000 randomly-chosen physicians
participate each year in a multi-stage, geographically clustered probability sample. Oﬃce visits serve as the unit of analysis.
Consistent with the previous analytic period (Study 1, 1993–2007),
NAMCS used the International Classiﬁcation of Diseases, 9th Revision,
Clinical Modiﬁcation (ICD-9-CM) (ICD-9-CM, 1996) for 2008–2015.
Key outcomes of interest, matching those of the previous analysis, were:

1.1. Sleeplessness-related outcomes of physician oﬃce visits, over time
To provide a 23-year trend arc, we ﬁrst describe results from Study
1 (1993–2007) (Moloney et al., 2011) and then results from the current
analyses (Study 2, 2008–2015). Fig. 1 provides a graphic representation
of trends 1993–2015. Study 2 results are presented in Table 2.
During Study 1, complaints of sleeplessness approximately doubled
(from 2.7 million to 5.7 million). Throughout Study 2, sleeplessness
complaints remained relatively stable (5.4 million in 2008, 5.7 million
in 2015). Insomnia diagnoses, however, steadily increased over 23
years, from 800,000 in 1993 to 6.1 million in 2007, and from 6.6
million in 2008 to 9.4 million in 2015. Near the end of Study 1 (in
2006), insomnia diagnoses began to outpace sleeplessness complaints.
This trend persisted throughout Study 2.
In Study 1, BDZ prescriptions increased from about 2.5 million to
3.7 million; NBSH prescriptions increased from 540,000 to 16.2 million.
During the 23-year period, NBSH prescriptions were on the rise,
peaking in 2011 at 22 million, before subsequently declining. In 2015,
just 14.5 million NBSH prescriptions were written.
In Study 1, all sleeplessness-related outcomes of physician oﬃce
visits (complaint of sleeplessness, insomnia diagnosis, BDZ and NBSH
prescriptions) increased signiﬁcantly over time. In Study 2, NBSH
prescriptions had a statistically signiﬁcant negative linear slope over
time, reﬂecting a signiﬁcant downward prescription trend. The nonsigniﬁcant slopes for all other outcomes suggest that there was no
steady increase or decrease in trends. Despite their downward trajectory during 2008–2015, NBSH prescriptions far outpaced all other
outcomes in Study 2.

• Sleeplessness as reason for oﬃce visit (deﬁned as complaints of
•
•

“can't sleep,” “trouble falling asleep,” or “sleeplessness” [NCHS code
1135.1]).
Insomnia diagnosis (ICD-9 codes: 78059, 78056, 78055, 78052,
78050, 32780, 32709, 32702, 32701, 32700, 30749, 30748, 30747,
30746, 30745, 30742, 30741, 30740).
Prescription of sedative-hypnotics (BDZ and NBSH) FDA-approved
for insomnia. (Rasu, Shenolikar, Nahata, & Balkrishnan, 2005)
(Please see Table 1).

To maintain consistency with Study 1 and examine whether the
medicalization of sleeplessness persisted over time at the interactional
level, we used svy commands in Stata Version 15 (StataCorp LP, College
Station, TX) to calculate means with 95% conﬁdence intervals for the
outcomes of interest (complaint, diagnosis, and prescriptions). We then
computed national estimates (in millions) for each outcome for the
present study (Study 2, 2008–2015). We also estimated rates for each
outcome by age group (18–44, 45–64, and ≥65 years), per 10,000
oﬃce visits. To avoid small cell sizes, age group data were combined
into two-year increments. We used NAMCS-provided sample weights to
adjust for complex survey design. To test for the signiﬁcance of the
linear trajectory, we ran a series of bivariate linear models by regressing
estimates for each outcome of interest on year. The regression coeﬃcients reﬂect average change in each of the four outcomes annually
over Study 2. Linear correlation coeﬃcients were calculated to examine
the strength of the association. Population estimates with 95% conﬁdence intervals, regression coeﬃcients (slopes), and correlation
coeﬃcients are reported in Tables 2 and 3, respectively.
Starting in 2012, the NAMCS sampling design changed, splitting the
oﬃce-based physician component from the Community Health Center
(CHC) component. As a result, 2012–2015 NAMCS public data ﬁles only
include data on visits to oﬃce-based physicians. To accommodate this
change, data on CHC visits for the 2008–2011 study period were

1.2. Sleeplessness-related outcomes of physician oﬃce visits over time, by
age
Throughout Study 1, adults ages 65 years and older were less likely
to visit a physician because of sleeplessness or receive an insomnia
diagnosis, when compared to those 18–44 or 45–65. As seen in Table 3,
these trends continued in Study 2. During Study 2 adults ages 45–64
had the highest rates of sleeplessness, followed closely by adults ages
18–44. Similarly, adults ages 45–64 had the highest rates of insomnia
diagnoses until 2014–2015, when they were outpaced by those 18–44.
In Study 1, adults ages 65 + had the highest BDZ prescription rates
and this trend continued for Study 2 (BDZ prescription range
2008–2015: 42.1–64.3/10,000 visits). Adults ages 45–64 had a steadily
declining rate of BDZ prescriptions ranging from 56.5 prescriptions/
10,000 visits in 2008–2009 to 29.4 prescriptions/10,000 visits in
2014–2015. The youngest age group (18–44) ranged from 20.5 to 26.1
prescriptions/10,000 visits across Study 2.
NBSH prescription rates, across all age groups, were consistently
higher than those of BDZ during Study 2. Like Study 1, adults ages
45–64 had the highest NBSH prescription rates (range 248.9–338.9/
10,000 visits) and adults ages 18–44 had the lowest NBSH prescription
rates (range 139.5–172.1/10,000 visits). Adults ages 65 + ranged from
a high of 278.5 NBSH prescriptions/10,000 visits in 2010–2011 to a
low of 164.9 NBSH prescriptions/10,000 visits in 2014–2015. The
slopes for all sleeplessness-related outcomes 2008–2015, by age group,
were not statistically signiﬁcant, suggesting a lack of a consistent trend.

Table 1
Benzodiazepine and nonbenzodiazepine sedative hypnotics approved for insomnia by the Food and Drug Administration (Rasu et al., 2005).
Brand Name
Benzodiazepines
Prosom
Dalmane
Doral
Restoril
Restoril
Non-benzodiazepines
Ambien, Ambien CR
Sonata
Lunesta
Rozerem

Generic Name

NAMCS Medication Code

Estazolam
Flurazepam
Quazepam
Temazepam
Temazepam

d00915
d00238
d00917
d00384
d00397

Zolpidem
Zaleplon
Eszopiclone
Ramelteon

d00910
d04452
d05421
d05578
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Table 2
Unweighted numbers and weighted estimates (in millions) along with 95% conﬁdence intervals of sleeplessness-related complaints, insomnia diagnoses, and prescriptions for benzodiazepine and nonbenzodiazepine sedative-hypnotics as a result of physician oﬃce visits: United States, 2008–2015
Year

Unweighted No. of Physician
Oﬃce Visits by Year (Weighted
Estimatesa)

2008
28,741
2009
32,281
2010
31,229
2011
30,872
2012
76,330
2013
54,873
2014
45,710
2015
28,332
Model Statisticsb
Slope, b
Correlation, r

(768.2)
(829.6)
(803.3)
(763.7)
(757.6)
(771.6)
(745.9)
(841.2)

Sleeplessness Complaints,
Weighted Estimated No. (95%
CI)a

Insomnia Diagnoses,
Weighted Estimated No.
(95% CI)a

BDZ Prescriptions, Weighted
Estimated No. (95% CI)a

NBSH Prescriptions, Weighted
Estimated No. (95% CI)a

5.4
5.2
5.5
3.7
4.3
4.0
5.4
5.7

6.6
6.4
6.1
7.1
6.1
7.1
6.7
9.4

3.7
4.2
2.7
3.2
3.7
3.1
3.1
1.9

19.1
19.8
19.1
22.0
16.7
16.8
16.8
14.5

(3.7,
(4.0,
(4.0,
(2.7,
(3.6,
(3.1,
(4.4,
(3.8,

7.1)
6.4)
6.9)
4.6)
5.0)
4.9)
6.4)
7.6)

−6916
-.0224

(5.2,
(4.9,
(4.3,
(5.4,
(5.2,
(5.7,
(5.5,
(5.3,

277890
.6319

8.1)
7.8)
7.9)
8.8)
7.0)
8.4)
7.9)
13.6)

(2.7,
(3.0,
(1.9,
(2.3,
(3.1,
(2.4,
(2.3,
(1.1,

4.8)
5.4)
3.4)
4.2)
4.4)
3.8)
4.0)
2.8)

−189,290
-.6576

(16.3,
(16.6,
(16.1,
(18.0,
(15.0,
(14.9,
(14.9,
(11.0,

21.8)
22.9)
22.0)
25.9)
18.3)
18.8)
18.8)
18.0)

−699,628c
-.7367

Note: BDZ = benzodiazepine; NBSH = nonbenzodiazepine sedative hypnotic; CI = conﬁdence interval.
a
Estimates are provided in millions.
b
For model statistics, b is the regression coeﬃcient (slope) from bivariate linear regression of national estimates for each outcome of interest on year; r is the
temporal correlation of variable with year.
c
Signiﬁcant slope at = P < 0.05 as a result of bivariate regression analysis.

Discussion

perception, stricter practice recommendations, and reduced spending
on NBSH direct-to-consumer advertising (DTCA).
Shifts in these factors coincide with the precipitous drop in NBSH
prescriptions in 2012 (16.7 million, down from nearly 22 million in
2011). Although numerous studies prior to 2012 linked sedative-hypnotic use to dangerous side eﬀects and potential for abuse (Glass,
Lanctot, Herrmann, Sproule, & Busto, 2005; Longo & Johnson, 2000),
the landmark ﬁndings of Kripke, Langer, and Kline demonstrated a
clear “dose-response” eﬀect between sedative-hypnotic use and morbidity and mortality hazards (Kripke et al., 2012). These ﬁndings,
published in early 2012, also generated widespread media coverage and
attention-grabbing headlines (e.g., “Researchers: Sleeping Pills Can Kill
You,” “Here's Why Experts say Sleeping Pills are as Bad as Cigarettes”)
(Kakade, 2012; Mullur, 2012). The news media increasingly inﬂuences
American ideas and policy related to health, illness, and treatment
(Gollust, Eboh, & Barry, 2012). High-proﬁle media coverage of stories
on the deleterious health outcomes associated with drug use (e.g, estrogen/progesterone replacement correlations with breast cancer) has
been linked to reduced prescription rates, and this is at least partially
attributable to consumers (Haas, Kaplan, Gerstenberger, & Kerlikowske,
2004).
Physicians, too, are inﬂuenced by both scientiﬁc studies and public
perception, particularly when paired with more conservative practice
recommendations (Grimshaw et al., 2004). In recent years, the welldocumented harms of sedative-hypnotics have resulted in calls to avoid
their use as ﬁrst-line insomnia therapy (Qaseem et al., 2016). Recommendations for older adults are particularly strict. In 2012, the
American Geriatrics Society recommended avoiding BDZ for insomnia
and imposed stricter limitations (no more than 90 days) on NBSH use
(American Geriatrics Society Beers Criteria Update Expert, 2012). In
2015 they updated their recommendations to complete avoidance of all
sedative-hypnotics for older adults (American Geriatrics Society Beers
Criteria Update Expert Panel, 2015).
Changes in DTCA may also impact prescription rates. As recently
described by Barbee and colleagues (Barbee et al., 2018), DTCA for
NBSH has fallen oﬀ steeply in recent years.3 For context, makers of
Ambien and Ambien CR, the most popular of the newer-generation
sedative-hypnotics spent $147 million on DTCA in 2008, a time of
economic recessesion (Weinstein, 2013). DTCA expenditures for Ambien CR have since declined, as is common among medications nearing

This study oﬀers an updated analysis of sleeplessness-related outcomes of U.S. physician oﬃce visits and provides some evidence that
the medicalization of sleeplessness may be waning at the level of patient-physician interaction. Contrary to the ﬁrst hypothesis, that
sleeplessness complaints, insomnia diagnoses, and sedative-hypnotic
prescriptions would continue to increase signiﬁcantly over time, the
only statistically signiﬁcant trend over the study period was the reduction of NBSH prescriptions. The number of NBSH prescriptions in
2015 was approximately 14.5 million, a 34% decrease since the trend's
peak of nearly 22 million in 2011. These trends diﬀer substantially
when compared to 1993–2007 analyses, when all sleeplessness-related
trends over time were positive and statistically signiﬁcant, and NBSH
prescriptions increased 30-fold (Moloney et al., 2011).
Our second hypothesis, that sleeplessness complaints would lag
behind insomnia diagnoses and NBSH prescriptions, was supported. In
2011, for instance, NBSH prescriptions outpaced insomnia diagnoses
more than 3 to 1, and sleeplessness complaints nearly 6 to 1. Even at
their lowest rate of prescription (in 2015) NBSH prescription rates were
still 1.5 times higher than insomnia diagnoses, and 2.5 times higher
than sleeplessness complaints. Throughout the 2008–2015 analytic
period, insomnia diagnoses outpaced sleeplessness complaints; this
trend was reversed prior to 2006. Generally, these trends support the
medicalization hypothesis that pharmaceutical “solutions” are not always directly linked to formal complaint or diagnosis (Moloney et al.,
2011).
Our third hypothesis, regarding age groups and sleeplessness-related outcomes, was also supported. While older age is associated with
increased sleep disruption (Colten & Altevogt, 2006), adults ages
65 + in this sample received fewer insomnia diagnoses compared to
those 18–44 and 45–64. Across the analytic period, the highest rates of
insomnia diagnoses and NBSH prescriptions were observed among
adults ages 45–64. Compared to younger adults, those ages 65 + received a BDZ prescription at a higher rate. However, BDZ prescription
rates were consistently lower than NBSH prescription rates, for all age
groups. Given BDZ's decades-long reputation as a “social problem,”
these lower rates are not surprising (Gabe & Bury, 1988).
While causal conclusions cannot be drawn from these data, we
speculate that two engines of medicalization – consumerism and physicians – may be inﬂuencing the medicalization of sleeplessness at the
level of patient-physician interaction. Put simply, patients may be less
likely to request these drugs, and providers less likely to prescribe them.
But why? Factors worthy of consideration include negative public

3
BDZ have been generic for decades, and thus are not marketed to consumers.
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generic status (Shapiro, 2016). In contrast, makers of Intermezzo, a new
NBSH introduced in 2012, spent just $29 million on the ﬁrst six months
of marketing; sales have been underwhelming (Smith, 2013).
Although we focus here on the oﬃce visit interaction and subsequent outcomes, we would be remiss if we did not acknowledge
larger forces that inﬂuence the medicalization of sleeplessness.
Quantitative and qualitative research has identiﬁed multiple social and
behavioral factors (e.g., career uncertainty, near-constant use of lightproducing technology, worry over children or aging parents) that are
closely linked to sleep loss and request for sleep aids (Moloney, 2017;
Seidel, Yorgason, Polenick, Zarit, & Fingerman, 2017; Thomee,
Harenstam, & Hagberg, 2011). Additional factors, particularly relevant
to the United States and its aging, Baby Boom generation, that fuel the
multi-billion dollar “Sleep-Industrial Complex” include: enhancement
culture (self-transformation through techno-science), commodiﬁcation
of health (creation of niche health-services and products), and a “productivity imperative” (maximizing productivity in a 24/7 work culture)
(Barbee et al., 2018). Future research could speciﬁcally investigate the
extent to which these and other factors contribute to changing attitudes
and practices related to sedative-hypnotics.
Additional research might also consider the salience of related
theoretical constructs such as pharmaceuticalization (Williams et al.,
2008) and healthicization (Hislop & Arber, 2003). The general medicalization framework we have used to interpret these data construes
trends in either diagnosis or treatment as indicative of medicalization
(Conrad and Cockerham, 2013). However, our analyses might be usefully expanded upon through further consideration of whether, or the
degree to which, declines in pharmaceuticalization account for the
decline in sedative-hypnotic prescriptions that stand in contrast to
rising insomnia diagnoses. It is also possible that declining sedativehypnotic prescriptions are linked to a rise in healthicization, wherein
consumers eschew medication and embrace personalized, lifestyle
changes intended to improve sleep (e.g., no caﬀeine after 4PM, no
screen time an hour before bed). Importantly, we cannot conclude that
our data oﬀer evidence of the demedicalization of sleeplessness as a
whole, as we focus on outcomes at the interactional level only
(Williams, 2004).
While this analysis provides useful updates on prior research, several limitations should be noted. The NAMCS dataset was neither designed nor intended to measure the medicalization process. The unit of
analysis is the oﬃce visit, which is not equivalent to patient outcomes.
Although NAMCS allows us to track prescription rates over time, we
have no way of knowing if prescriptions were ﬁlled and medication
ingested. We limited the scope of our analyses to only drugs that are
FDA-approved for insomnia (Rasu et al., 2005), thus we cannot account
for drugs (over-the-counter or prescription) that are primarily intended
for other health concerns, but commonly used for sleeplessness (e.g.,
Benadryl). Future work may wish to analyze a wider range of medications. Further, the elimination of the Community Health Center visits
may limit the generalizability of the ﬁndings within certain groups, and
downwardly bias our estimates.
Despite these limitations, this work contributes to the medicalization literature generally, and the medicalization of sleeplessness literature in particular, by oﬀering quantitative evidence that the medicalization of sleeplessness may be on the decline. To our knowledge,
this is the ﬁrst study to oﬀer an updated look at sleeplessness-related
outcomes (i.e., sleeplessness complaint, insomnia diagnosis, prescription of BDZ or NBSH) of physician oﬃce visits 2008–2015 and compare
these outcomes to 1993–2007 trends, thus providing a 23-year trend
arc. Although we speculate that the increasingly negative portrayals of
sedative-hypnotics, combined with shifting practice recommendations,
and decreased DTCA have led to reduced consumerism and/or physician compliance in the case of sedative-hypnotics for sleeplessness,
future research should explore these dynamics in more detail.
Population health may be improved by continued awareness-raising
of sedative-hypnotic harms among both doctors and patients. It is also

Note: BDZ = benzodiazepine; NBSH = nonbenzodiazepine sedative hypnotic.
a
For model statistics, b is the slop from bivariate regression of variable on year-range midpoint; r is the temporal correlation of variable with year-range midpoint. Ranges are two years.
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National weighted estimates of sleeplessness-related complaints, diagnoses, and prescriptions for benzodiazepine and nonbenzodiazepine sedative hypnotics, per 10,000 physician oﬃce visits, by age group: United States,
2008–2015
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Fig. 1. Sleeplessness-related trends of complaint, insomnia diagnosis, benzodiazepine (BDZ) and nonbenzodiazepine sedative hypnotic (NBSH) prescription as a
result of physician oﬃce visits: United States, 1993–2015.

imperative to address behavioral or social causes of sleeplessness and
treat these root causes with appropriate behavioral or psychological
therapies. More broadly impactful, however, would be the implementation of work and school schedules that more closely adhere to
shifting circadian rhythms over the life course (e.g., delayed school
start time for teenagers), education programs (e.g., sleep hygiene) and
eliminating daylight savings time (Barnes & Drake, 2015). Further, the
addition of items reﬂecting the use of eﬀective well-validated and
standardized non-pharmacological treatment protocols (e.g., cognitive
behavioral therapy) occurring in clinical encounters in national databases like NAMCS would round out the picture for studies of this kind.
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